ABN Amro Investment Solutions Invests $2.79 Million in Abbott Laboratories $ABT

ABN Amro Investment Solutions acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 20,516 shares of the healthcare product maker’s stock, valued at approximately $2,790,000.

A number of other hedge funds have also recently made changes to their positions in ABT. Candriam S.C.A. grew its holdings in Abbott Laboratories by 63.8% during the 2nd quarter. Candriam S.C.A. now owns 1,046,883 shares of the healthcare product maker’s stock valued at $142,393,000 after buying an additional 407,813 shares in the last quarter. Calamos Advisors LLC lifted its holdings in shares of Abbott Laboratories by 5.4% in the 2nd quarter. Calamos Advisors LLC now owns 509,336 shares of the healthcare product maker’s stock worth $69,275,000 after acquiring an additional 26,310 shares during the last quarter. Hudock Inc. raised its holdings in shares of Abbott Laboratories by 2.7% in the second quarter. Hudock Inc. now owns 3,405 shares of the healthcare product maker’s stock worth $463,000 after buying an additional 89 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Abbott Laboratories by 4.4% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 262,889 shares of the healthcare product maker’s stock valued at $35,756,000 after purchasing an additional 11,036 shares during the period. Finally, Bailard Inc. boosted its holdings in shares of Abbott Laboratories by 13.3% in the second quarter. Bailard Inc. now owns 99,808 shares of the healthcare product maker’s stock valued at $13,575,000 after purchasing an additional 11,734 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.0%

NYSE ABT opened at $130.59 on Friday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm’s 50-day moving average is $130.38 and its two-hundred day moving average is $131.35. The stock has a market capitalization of $227.08 billion, a P/E ratio of 16.36, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period in the prior year, the firm earned $1.21 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Analyst Upgrades and Downgrades

ABT has been the topic of several research reports. Jefferies Financial Group lifted their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. Daiwa Capital Markets upped their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, Evercore ISI dropped their target price on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.